Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population
ESMO Open ( IF 7.3 ) Pub Date : 2024-03-08 , DOI: 10.1016/j.esmoop.2024.102389 Q. Lu , N. Wang , K. Jiang , H. Zhou , P. Zhang , J. Zhang , S. Wang , P. Sun , F. Xu
ESMO Open ( IF 7.3 ) Pub Date : 2024-03-08 , DOI: 10.1016/j.esmoop.2024.102389 Q. Lu , N. Wang , K. Jiang , H. Zhou , P. Zhang , J. Zhang , S. Wang , P. Sun , F. Xu
Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical practice. In this study, we aimed to identify potential actionable targets in brain metastases (BMs) utilising the FoundationOne® CDx (F1CDx). Formalin-fixed paraffin-embedded archived specimens including 16 primary breast tumours (PTs), 49 BCBMs and 7 extracranial metastases (ECMs) from 54 patients who underwent surgery for BCBM were tested using F1CDx. Tumour-infiltrated lymphocytes (TILs) of BMs were also tested using haematoxylin–eosin staining. The median tumour mutational burden (TMB) and TILs in BMs were 5.0 (range 0-29) mut/Mb and 1.0% (range 0%-5.0%), respectively. High TMB (≥10 mut/Mb) was detected in four cases (8%). Genomic alterations (GAs) were detected in all samples. The top-ranked somatic mutations in BMs were (82%), (35%), (22%), (14%) and (14%) and the most prevalent copy number alterations were (64%), (36%), (32%), (30%) and (30%). The most prevalent GAs were relatively consistent between paired PTs and BMs. Actionable GAs were detected in 94% of all BMs. Consistent rate in actionable GAs was 38% (6/16) between paired PTs/ECMs and BMs. Compared to matched PTs/ECMs, additional actionable GAs (, , , and ) were discovered in 31% (5/16) of the BMs. TMB and TILs were relatively low in BCBMs. Comparable consistency in actionable GAs was identified between BCBMs and matched PTs/ECMs. It was, therefore, logical to carry out genomic testing for BCBMs to identify potential new therapeutic targets when BCBM specimens were available, as ∼31% of samples carried additional actionable GAs.
更新日期：2024-03-08
京公网安备 11010802027423号